Clinical guidance for smallpox vaccine use in a postevent vaccination program

MMWR Recommendations and Reports

Volumn 64, Issue 2, 2015, Pages 1-32

  Petersen, Brett W ^a   Damon, Inger K ^a   Pertowski, Carol A ^b   Meaney Delman, Dana ^a   Guarnizo, Julie T ^a   Beigi, Richard H ^c   Edwards, Kathryn M ^d   Fisher, Margaret C ^e   Frey, Sharon E ^f   Lynfield, Ruth ^g   Willoughby, Rodney E ^h  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e MONMOUTH MEDICAL CENTER   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MINNESOTA DEPARTMENT OF HEALTH   (United States)

^h Children's Hospital of Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE;

BIOLOGICAL ACCIDENT; BIOLOGICAL WARFARE; DISASTER PLANNING; HUMAN; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; SMALLPOX; STANDARDS; UNITED STATES;

BIOHAZARD RELEASE; BIOTERRORISM; DISASTER PLANNING; HUMANS; IMMUNIZATION PROGRAMS; PRACTICE GUIDELINES AS TOPIC; SMALLPOX; SMALLPOX VACCINE; UNITED STATES;

EID: 84927169940     PISSN: 10575987     EISSN: 15458601     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988.
2. Koplow DA. Smallpox: the fight to eradicate a global scourge. Berkeley, CA: University of California Press; 2003.
3. CDC. Public Health Service recommendations on smallpox vaccination. MMWR Morb Mortal Wkly Rep 1971;20:339.
4. Henderson DA, Arita I. The smallpox threat: a time to reconsider global policy. Biosecur Bioterror 2014;12:117-21.
5. Henderson DA, Inglesby TV, Bartlett JG, et al. Working Group on Civilian Biodefense. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281:2127-37.
6. CDC. Vaccinia (smallpox) vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(No. RR-14).
7. Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001;50(No. RR-10).
8. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52(No. RR-7).
9. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. guidance for clinicians. MMWR Recomm Rep 2003;52(No. RR-4).
10. World Health Organization. International health regulations (2005). Geneva, Switzerland: World Health Organization; 2006.
11. CDC. Newly licensed smallpox vaccine to replace old smallpox vaccine. MMWR Morb Moratal Wkly Rep 2008;57:207-8.
12. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
13. World Health Organization Expert Committee on Smallpox Eradication. Second report. World Health Organ Tech Rep Ser 1972;493:1-64.
14. Rao AR. Smallpox. 1st ed. Bombay, India: Kothari Book Depot; 1972.
15. World Health Organization. World Health Organization fact sheet on smallpox. Geneva, Switzerland: World Health Organization; 2001.
16. Dixon CW. Smallpox. London, UK: Churchill; 1962.
17. Martin DB. The cause of death in smallpox: an examination of the pathology record. Mil Med 2002;167:546-51.
18. Foege WH, Millar JD, Henderson DA. Smallpox eradication in West and Central Africa. Bull World Health Organ 1975;52:209-22.
19. Basu RN, Jezek Z, Ward NA; World Health Organization. Regional Office for South-East Asia. The eradication of smallpox from India. New Delhi, India: World Health Organization, South-East Asia Regional Office; 1979.
20. Nishiura H. Smallpox during pregnancy and maternal outcomes. Emerg Infect Dis 2006;12:1119-21.
21. Rao AR, Prahlad I, Swaminathan M, Lakshmi A. Pregnancy and smallpox. J Indian Med Assoc 1963;40:353-63.
22. Lane JM. Remaining questions about clinical variola major. Emerg Infect Dis 2011;17:676-80.
23. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346:1300-8.
24. Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005;11:1005-11.
25. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008;121:1058-64.
26. Massoudi MS, Barker L, Schwartz B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J Infect Dis 2003;188:973-6.
27. Rao AR, Jacob ES, Kamalakshi S, Appaswamy S, Bradbury BD. Epidemiological studies in smallpox. A study of intrafamilial transmission in a series of 254 infected families. Indian J Med Res 1968;56:1826-54.
28. Heiner GG, Fatima N, McCrumb FR Jr. A study of intrafamilial transmission of smallpox. Am J Epidemiol 1971;94:316-26.
29. Sommer A. The 1972 smallpox outbreak in Khulna Municipality, Bangladesh. II. Effectiveness of surveillance and containment in urban epidemic control. Am J Epidemiol 1974;99:303-13.
30. Sarkar JK, Mitra AC, Mukherjee MK, De SK. Virus excretion in smallpox. 2. Excretion in the throats of household contacts. Bull World Health Organ 1973;48:523-7.
31. Downie AW, St Vincent L, Meiklejohn G, et al. Studies on the virus content of mouth washings in the acute phase of smallpox. Bull World Health Organ 1961;25:49-53.
32. Mack TM, Thomas DB, Muzaffar Khan M. Epidemiology of smallpox in West Pakistan. II. Determinants of intravillage spread other than acquired immunity. Am J Epidemiol 1972;95:169-77.
33. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970;43:669-79.
34. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972; 125:161-9.
35. Gelfand HM, Posch J. The recent outbreak of smallpox in Meschede, West Germany. Am J Epidemiol 1971;93:234-7.
36. Mack T. A different view of smallpox and vaccination. N Engl J Med 2003;348:460-3.
37. CDC. Smallpox Response Plan and Guidelines (Version 3.0). Atlanta, GA: US Department of Health and Human Services, CDC; 2002. Available at http://www.bt.cdc.gov/agent/smallpox/response-plan.
38. Courtney B, Sherman S, Penn M. Federal legal preparedness tools for facilitating medical countermeasure use during public health emergencies. Med Ethics (Burlingt, Mass) 2013;41(Suppl 1):22-7.
39. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007;25:8562-73.
40. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009;8:13-24.
41. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24:2065-70.
42. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010;28:1209-16.
43. Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006;55(No. RR-1).
44. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008;17:555-64.
45. Frey SE, Newman FK, Kennedy JS, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009;27:1637-44.
46. Sanofi-Pasteur. ACAM2000 (Smallpox [Vaccinia] Vaccine, Live) [Package insert]. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142572.pdf.
47. Rosenthal S, Merchlinsky M, Chowdhury M. VRBPAC background document: ACAM2000 (live vaccinia virus smallpox vaccine). Washington, DC: Food and Drug Administration; 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B2-01.pdf.
48. Food and Drug Administration. What is a serious adverse event? Washington, DC: Food and Drug Administration; 2014. Available at http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.
49. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-6.
50. Food and Drug Administration. Acambis I. ACAM2000 Smallpox Vaccine: Vaccines and Related Biological Products Advisory Committee (VRBPAC) briefing document. Washington, DC: Food and Drug Administration; 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292b2-02.pdf.
51. Ryan MA, Seward JF; Smallpox Vaccine in Pregnancy Registry Team. Pregnancy, birth, and infant health outcomes from the National Smallpox Vaccine in Pregnancy Registry, 2003-2006. Clin Infect Dis 2008;46(Suppl 3):S221-6.
52. Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005;294:2734-43.
53. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005;23:2078-81.
54. Mora LF, Khan AH, Sperling LS. Cardiac complications after smallpox vaccination. South Med J 2009;102:615-9.
55. Eckart RE, Love SS, Atwood JE, et al.; Department of Defense Smallpox Vaccination Clinical Evaluation Team. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004;44:201-5.
56. Swerdlow DL, Roper MH, Morgan J, et al. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003. Clin Infect Dis 2008;46 Suppl 3:S234-41.
57. Halsell JS, Riddle JR, Atwood JE, et al.; Department of Defense Smallpox Vaccination Clinical Evaluation Team. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289:3283-9.
58. Arness MK, Eckart RE, Love SS, et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004;160:642-51.
59. Morgan J, Roper MH, Sperling L, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis 2008; 46(Suppl 3):S242-50.
60. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
61. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-9.
62. Talbot TR, Stapleton JT, Brady RC, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004;292:1205-12.
63. Frey SE, Winokur PL, Salata RA, et al. Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario. Vaccine 2013;31:3025-33.
64. Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 2013;207:749-58.
65. Walsh SR, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013;207:1888-97.
66. Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009;90:1962-6.
67. Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978;41:225-34.
68. Garza NL, Hatkin JM, Livingston V, et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 2009;27:5496-504.
69. Keckler MS, Carroll DS, Gallardo-Romero NF, et al. Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges. J Virol 2011;85:7683-98.
70. Earl PL, Americo JL, Wyatt LS, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 2008;105:10889-94.
71. Kołodziej M, Joniec J, Bartoszcze M, Gryko R, Kocik J, Knap J. Research on substances with activity against orthopoxviruses. Ann Agric Environ Med 2013;20:1-7.
72. CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;36:1-19.
73. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep 2008;57(No. RR-10).
74. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-95.
75. Garde V, Harper D, Fairchok MP. Tertiary contact vaccinia in a breastfeeding infant. JAMA 2004;291:725-7.
76. Baciu A; Institute of Medicine. Committee on Smallpox Vaccination Program Implementation. The smallpox vaccination program: public health in an age of terrorism. Washington, DC: National Academies Press; 2005.